2011-05-21 18:27 by Wolf Kroner

Teeth for the Convention on Biological Diversity

The World Intellectual Property Organization WIPO will work on the legal instruments for effective protection of genetic resources in 2012/2013. To what extent Access-and-Benefit Sharing are enforced within the Convention on Biological Diversity (CBD)? An outlook on unresolved issues and the road ahead to ensure worldwide compliance.

2011-09-04 06:30

Plants are Nature’s Best Chemists

In a vivid account Peter Welters, CEO of Phytowelt GreenTechnologies argues for industrial plant biotechnology. He provides surprising examples which range from pharma, chemicals, textiles, cosmetics, renewable energies, to foods, and demonstrate untapped potentials for cost reductions and creating added value for customers.

2012-01-01 13:28

Impact on Greece: Eurasia-Europe gas and oil pipelines

Iδρυμα Οικονομικών & Βιομηχανικών Ερευνών (I.O.B.E.), a private Greek economic research institute, has published an analysis on the impact of natural gas and oil pipelines.

2011-10-11 11:03

Customs Sequencing Markets

A market estimate by a veteran in the business and an evaluation of the next two to three years..How to avoid that economies of scale and novel technologies become a trap.

Read more … Customs Sequencing Markets

PHARMA INDUSTRY VOICES ON STEM CELLS

2010-02-10 09:16

Doing our business a little bit differently than the others in industry

January 2010. At issue are other business models than those based on pharmacological treatments, says Dr. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk in an interview with B2Bioworld on stem cell applications in the pharmaceutical industry with some comments to competitors like Eli Lilly, Pfizer, or Eli Lilly, Sanofi-Aventis.

2010-02-10 09:10

Triggering Regenerative Functions with Transplanted Cells and Small Molecules

February 2010. What requirements stem technologies have to fulfil? What is the relationship to biomarker development? Which types of stem cells are most promising in order to meet Sanofi-Aventis’ strategic development goals? Prof. Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville (FR) describes in the interview with B2Bioworld, how his company approaches stem cells (including iPS cells), the role for small molecule development, and needs for complementary technologies.

2010-02-10 08:36

We are obliged to more and more move away from animal models

January 2010. In an interview with B2Bioworld Prof. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies and outlines corporate responsibilities, including a comment on BI’s patenting in the field.